rTMS Induced Reduction in M1 Excitability

May 28, 2026 updated by: Zachary Riley, Indiana University

The Effects of rTMS Induced Reduction in M1 Excitability on Early-online Learning and Retention in Dexterous Video-game Task

When learning a new skill, much of the improvement comes from small alterations the brain makes with each repetition during practice, but this isn't the only time that improvements are made during the learning process. Individuals also get better at the motor skills during the time between practices, through a process called "consolidation." It is known that an area of the brain called the primary motor cortex is involved in learning during active practice, but the investigators want to study if the primary motor cortex is important for consolidation. The investigators will examine how lowering the activity in this brain region affects your ability to consolidate learning to play a song on the videogame Guitar Hero.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Research employing rTMS-induced reductions in excitability showed that M1 had a large role in consolidation after practice, but was not responsible for the improvements that occur during practice. Though this study used a simple finger tapping task, additional studies have shown the role of M1 in task consolidation with ballistic movements and dynamic force-field learning tasks, while using rTMS to reduce cortical excitability. The main issue with previous studies is that they have been limited to a single digit, single joint, or non-transferrable laboratory tasks. This limits the application of these studies to real world scenarios, and shows the need for further research into this interaction. Therefore, we intend to examine the effect of an rTMS-induced reduction in M1 excitability, on the learning of a dynamic, two-handed video game task (Guitar Hero). This is important because it will help explain the role of M1 in learning complex, bimanual tasks. Our study will also directly address how M1 contributes to the fast and slow consolidation of dynamic, coordinated actions that more closely resemble real-world activities (video games). Ultimately, this knowledge is crucial to the development of targeted non-invasive brain stimulation protocols that could aid in the rehabilitation of patients with motor dysfunction, in which relearning complex coordinated motor tasks is a primary goal.

Objective(s)

  1. Primary Objective Our primary objective is to determine if short term inhibition of M1 with 1Hz rTMS (rTMS induced reductions in excitability) blocks the early online learning (fast and slow consolidation) that occurs when first playing a video game
  2. Secondary Objective Our secondary objective is to compare the amount of rTMS-induced reductions in excitability, measured with single pulse TMS motor-evoked potential cortical excitability, with the amount of fast and slow consolidation observed in playing the video game.

Study Type

Interventional

Enrollment (Estimated)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Zachary A Riley
  • Phone Number: 317-274-1487
  • Email: zariley@iu.edu

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • National Institute for Fitness and Sport
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Between ages 18 and 45 years old (to avoid any changes in the developing brain, or with aging).
  • Answer 'no' to questions 2 through 17 on the brain stimulation questionnaire as these factors can increase likelihood of adverse events with brain stimulation.
  • No neurological damage, disease, or dysfunction (nerve damage, chronic pain disorders, diabetic neuropathy, epilepsy) that affect the upper limbs and limit the ability to complete the study, and/or compromise the objectives of the study
  • No significant visual impairment that would prevent them from playing a video game.

Exclusion Criteria:

  • Currently prescribed and taking stimulant medication (Adderall, Ritalin, Vyvanse, etc.)
  • Consumption of over-the-counter stimulants such as caffeine or nicotine (coffee, soda, supplements, energy drinks, tobacco products, or other nicotine containing products such as gum, vape pens, etc...) 12 hours prior to entering the lab on the day of testing as this can directly affect cortical excitability. If a subject takes any of these substances 12 hours prior to the study visit they will be asked to reschedule for a later date.
  • Have played a real stringed instrument in the last 12 months (e.g. guitar, bass, violin)
  • Have played the videogame "Guitar Hero" on a traditional guitar controller in the last 12 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: rTMS stimulation group
this group will receive 15 minutes of repetitive transcranial magnetic stimulation of the motor cortex while seated quietly
in the arm/group descriptions
Other Names:
  • Sham
Placebo Comparator: SHAM stimulation group
This group will have the same stimulating wand placed over the head, but at a distance far enough away as to not activate the cortical neurons.
in the arm/group descriptions
Other Names:
  • Sham

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gaming outcome
Time Frame: 3 sessions, sessions 1 & 2 on the first day and session 3 on the follow-up day (next day)
Primary outcome measures will include comparing video game performance (number of correct notes played, overstrums) across the three testing sessions.
3 sessions, sessions 1 & 2 on the first day and session 3 on the follow-up day (next day)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cortical Changes
Time Frame: 3 sessions, sessions 1 & 2 on the first day and session 3 on the follow-up day (next day)
Secondary outcome measures will include correlating cortical excitability with the amount of learning observed in video game performance.
3 sessions, sessions 1 & 2 on the first day and session 3 on the follow-up day (next day)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Zachary Riley, Professor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2026

Primary Completion (Estimated)

April 23, 2027

Study Completion (Estimated)

April 23, 2027

Study Registration Dates

First Submitted

May 1, 2026

First Submitted That Met QC Criteria

May 8, 2026

First Posted (Actual)

May 14, 2026

Study Record Updates

Last Update Posted (Actual)

June 1, 2026

Last Update Submitted That Met QC Criteria

May 28, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 30610

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We do not plan to share study participant data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Motor Skills

Clinical Trials on rTMS

Subscribe